ArticleJBMR plus2026
Impact of FRAXplus adjustments vs FRAX on fracture risk classification in the Swiss Osteoporosis Registry.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FRAXplus complements the fracture risk assessment tool (FRAX) by incorporating additional risk factors to adjust 10-yr probabilities of major osteoporotic and hip fractures. We aimed to identify which adjustments most strongly influence fracture risk estimates and how they affect risk classification and treatment recommendations in Switzerland. We analyzed data from the Swiss Osteoporosis Registry (2015-2023), which captures all standard FRAX variables plus lumbar spine (LS) BMD, trabecular bone score (TBS), fall history in the previous year, oral glucocorticoid dosages, and the location and recency of prior fractures. Data on hip axis length and duration of type 2 diabetes were not available. A total of 28 708 individuals (88% women; mean age 65.8 ± 11.4 yr) were included, with a median 10-yr probabilities for major osteoporotic fracture (MOF) of 16% (interquartile range [IQR]: 9-24) using standard FRAX and 18% [IQR: 11-28] with FRAXplus adjustments. Most individuals (72%) had higher probabilities with FRAXplus (mean absolute increase: +4.8%), while 27% had lower probabilities (mean absolute decrease: -1.0%). TBS and LS minus FN T-score (LS - FN) influenced nearly all risk estimates, but differences between FRAX and FRAXplus were generally modest. At the individual level, ≥1 fall and recent vertebral or hip fractures produced the largest differences. Applying FRAXplus with Swiss intervention thresholds led to an upward reclassification in 16% of MOF estimates and a downward reclassification in 1%. In summary, FRAXplus adjustments significantly alter fracture risk estimates for most individuals. While LS BMD and TBS affect most probabilities, falls and recent vertebral or hip fractures have the largest absolute impact at the individual level, leading to clinically relevant changes in treatment recommendations according to Swiss guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.